Added to YB: 2025-11-18
Pitch date: 2025-11-14
TEM [neutral]
Tempus AI, Inc.
+3.95%
current return
Author Info
No bio for this author
Company Info
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
Market Cap
$12.5B
Pitch Price
$67.93
Price Target
N/A
Dividend
N/A
EV/EBITDA
-82.74
P/E
-59.11
EV/Sales
11.84
Sector
Life Sciences Tools and Services
Category
growth
TEM | Tempus AI Q3 2025 Financial Report Highlights
TEM (earnings): Rev +85% to $334M, first positive adj EBITDA $1.5M (vs $4M est), Q4 guidance $20M EBITDA. Genomics +117%, Insights bookings +38%. Gross margin 63.6% (+400bps). Acquired Paige for multimodal AI, 3 FDA approvals. At $68 vs DCF $55-65, overvalued despite strong execution.
Read full article (9 min)